Evaluation and immunohistochemical qualification of carbogen-induced DeltaR(2) as a noninvasive imaging biomarker of improved tumor oxygenation

Item does not contain fulltextPURPOSE: To evaluate and histologically qualify carbogen-induced DeltaR2 as a noninvasive magnetic resonance imaging biomarker of improved tumor oxygenation using a double 2-nitroimidazole hypoxia marker approach. METHODS AND MATERIALS: Multigradient echo images were acquired from mice bearing GH3 prolactinomas, preadministered with the hypoxia marker CCI-103F, to quantify tumor R2 during air breathing. With the mouse remaining positioned within the magnet bore, the gas supply was switched to carbogen (95% O2, 5% CO2), during which a second hypoxia marker, pimonidazole, was administered via an intraperitoneal line, and an additional set of identical multigradient echo images acquired to quantify any changes in tumor R2. Hypoxic fraction was quantified histologically using immunofluorescence detection of CCI-103F and pimonidazole adduct formation from the same whole tumor section. Carbogen-induced changes in tumor pO2 were further validated using the Oxylite fiberoptic probe. RESULTS: Carbogen challenge significantly reduced mean tumor R2 from 116 +/- 13 s(-1) to 97 +/- 9 s(-1) (P<.05). This was associated with a significantly lower pimonidazole adduct area (2.3 +/- 1%), compared with CCI-103F (6.3 +/- 2%) (P<.05). A significant correlation was observed between DeltaR2 and Deltahypoxic fraction (r=0.55, P<.01). Mean tumor pO2 during carbogen breathing significantly increased from 6.3 +/- 2.2 mm Hg to 36.0 +/- 7.5 mm Hg (P<.01). CONCLUSIONS: The combined use of intrinsic susceptibility magnetic resonance imaging with a double hypoxia marker approach corroborates carbogen-induced DeltaR2 as a noninvasive imaging biomarker of increased tumor oxygenation